BofA raises UiPath stock price target to $13 on execution view

BofA raised its UiPath price target to $13 from $12 while keeping an Underperform rating, citing a higher 2.8x EV/revenue multiple for calendar 2027 as execution prospects improve. The stock trades at $11.58, below both BofA’s target and InvestingPro’s fair value of $13.62, but BofA still sees a discount to peers justified by slower expected growth at 10% versus 13% for infrastructure software peers. Latest quarter results were mixed: EPS of $0.15 missed the $0.16 estimate, while revenue of $418.38 million beat consensus by 5.33%.

Analysis

The key signal is not the modest target bump itself, but that multiple sell-side models are converging on a lower-growth, higher-duration software multiple even as execution has improved. That usually means the market is treating PATH less like a pure software compounding story and more like a rightsized cash-flow asset whose upside depends on proving AI is additive rather than substitutive to its core workflow automation economics. In other words, the stock’s next rerating likely requires evidence that AI expands wallet share faster than it cannibalizes legacy automation demand.

The second-order winner may be the broader infrastructure-software complex if PATH can hold an elevated multiple despite sub-peer growth, because it would validate that buyers will pay for sticky margins and operating leverage even in a slower top-line regime. The loser is any vendor whose moat depends on task automation alone; if investors conclude that large-model copilots compress differentiation, then adjacent names with similar workflow exposure could see multiple pressure without needing an earnings miss.

Near term, the catalyst path is binary: a few quarters of clean revenue beats and sustained upward estimate revisions can keep the stock bid, but any slowdown in net new ARR or evidence that AI features are monetized via bundling rather than pricing power will reverse the move quickly. The valuation debate is also sensitive to timing: the market is looking out to 2027, so even small changes in long-range growth assumptions can move the stock 10-20% while fundamentals appear unchanged.

The contrarian take is that the current discount may already embed too much skepticism about displacement risk. If management can show that AI increases deployment speed and expands use cases, the market may be underestimating how much operating leverage can flow through a high-gross-margin base. But if AI merely defends share, not grows it, the lower multiple is justified and any rally should be sold into.

Key Decisions for Investors

• Short-dated bullish upside capture: buy PATH 2-3 month call spreads financed with out-of-the-money call sales; aim for a catalyst trade into the next earnings/guide update with ~2:1 payoff if the market rewards continued estimate revisions.
• Pair trade: long PATH / short a higher-multiple automation software peer basket over 1-2 quarters; the thesis is relative multiple convergence if PATH proves AI is additive to revenue rather than dilutive.
• If already long PATH, tighten risk ahead of the next print and use a 10-12% trailing stop; the stock is trading on sentiment around durability, so a single execution miss can compress the multiple faster than fundamentals change.
• For opportunistic value exposure, accumulate only on post-earnings selloffs that hold above recent support; the setup improves if the company can show another revenue beat plus raised full-year expectations.
• Avoid chasing the stock on headline target increases alone; wait for evidence of monetized AI adoption, because without it the rerating ceiling is likely limited to a modest multiple normalization.